

# John M Lachin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2316927/john-m-lachin-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

255  
papers

50,962  
citations

81  
h-index

225  
g-index

278  
ext. papers

58,800  
ext. citations

10.4  
avg, IF

7.36  
L-index

#	Paper	IF	Citations
255	Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC.. <i>BMJ Open Diabetes Research and Care</i> , <b>2022</b> , 10,	4.5	2
254	Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257154	3.7	1
253	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	5
252	Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2021</b> , 44, 1309-1314	14.6	1
251	Cost-efficient clinical studies with continuous time survival outcomes. <i>Statistics in Medicine</i> , <b>2021</b> , 40, 3682-3694	2.3	
250	Association of glycemia with insulin sensitivity and $\beta$ Cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107912	3.2	2
249	Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 1499-1505	14.6	4
248	Hyperglucagonemia Does Not Explain the $\beta$ Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. <i>Diabetes Care</i> , <b>2021</b> , 44, 1961-1969	14.6	2
247	Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Ophthalmology</i> , <b>2021</b> , 128, 554-560	7.3	2
246	Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 171, 108591	7.4	2
245	Association of Baseline Characteristics With Insulin Sensitivity and $\beta$ Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , <b>2021</b> , 44, 340-349	14.6	3
244	OGTT Glucose Response Curves, Insulin Sensitivity, and $\beta$ Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve $\beta$ Cell Function. <i>Diabetes Care</i> , <b>2021</b> , 44, 817-825	14.6	7
243	Residual $\beta$ Cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	15
242	Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 436-445	18.1	14
241	Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. <i>Journal of Diabetes Investigation</i> , <b>2021</b> ,	3.9	3
240	The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	5
239	Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). <i>Diabetes Care</i> , <b>2021</b> ,	14.6	6

238	Coronary Artery Disease Events and Carotid Intima-Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. <i>Journal of the American Heart Association</i> , <b>2021</b> , e022922	6	1
237	Nonparametric Statistical Analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2080-2084	27.4	9
236	Models to Assess the Association of a Semiquantitative Exposure With Outcomes. <i>American Journal of Epidemiology</i> , <b>2020</b> , 189, 1573-1582	3.8	2
235	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. <i>Diabetes</i> <b>2020</b> ;69:291-299. <i>Diabetes</i> , <b>2020</b> , 69, e7-e8	0.9	3
234	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , <b>2020</b> , 69, 1000-1010	0.9	44
233	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 867-874	14.6	26
232	Closed testing of each group versus the others combined in a multiple group analysis. <i>Clinical Trials</i> , <b>2020</b> , 17, 77-86	2.2	0
231	Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. <i>Pediatric Diabetes</i> , <b>2020</b> , 21, 1437-1446	3.6	3
230	Worst-Rank Score Methods-A Nonparametric Approach to Informatively Missing Data. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1670-1671	27.4	0
229	DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. <i>Nature Metabolism</i> , <b>2020</b> , 2, 744-762	14.6	17
228	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 2478-2484	14.6	8
227	Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. <i>Diabetes</i> , <b>2020</b> , 69, 2440-2445	0.9	0
226	The minimum intensity of a mixed exposure that increases the risk of an outcome. <i>Statistics in Medicine</i> , <b>2020</b> , 39, 4016-4024	2.3	
225	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 854-861	6.9	18
224	Association of Habitual Daily Physical Activity With Glucose Tolerance and $\beta$ Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 1521-1529	14.6	5
223	Lack of Durable Improvements in $\beta$ Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , <b>2019</b> , 42, 1742-1751	14.6	30
222	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 1284-1289	14.6	27
221	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2019</b> , 42, 883-890	14.6	37

220	Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 875-882	14.6	63
219	The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 1341-1349	8.4	24
218	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 657-664	14.6	24
217	RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES. <i>Endocrine Practice</i> , <b>2019</b> , 25, 1243-1254	3.2	1
216	Closed testing using surrogate hypotheses with restricted alternatives. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219520	3.7	0
215	Immune Complexes and the Risk of CVD in Type 1 Diabetes. <i>Diabetes</i> , <b>2019</b> , 68, 1853-1860	0.9	10
214	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> 2019;42:657-664. <i>Diabetes Care</i> , <b>2019</b> , 42, e137	14.6	
213	Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210367	3.7	3
212	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 128-139	18.1	119
211	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME <sup>2</sup> trial. <i>European Heart Journal</i> , <b>2018</b> , 39, 363-370	9.5	171
210	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 364-367	15.1	28
209	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , <b>2018</b> , 41, 596-603	14.6	44
208	Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. <i>Diabetes Care</i> 2017;40:655-662. <i>Diabetes Care</i> , <b>2018</b> , 41, e64	14.6	3
207	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , <b>2018</b> , 137, 119-129	16.7	252
206	Properties of composite time to first event versus joint marginal analyses of multiple outcomes. <i>Statistics in Medicine</i> , <b>2018</b> , 37, 3918-3930	2.3	2
205	What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?. <i>Journal of Diabetes and Its Complications</i> , <b>2018</b> , 32, 911-915	3.2	16
204	University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session). <i>Clinical Trials</i> , <b>2018</b> , 15, 366-385	2.2	
203	Intention-to-Treat: Overview <b>2018</b> , 1-10		

202	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves $\beta$ Cell Function and Improves HbA in New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , <b>2018</b> , 41, 1917-1925	14.6	56
201	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , <b>2018</b> , 41, 1887-1894	14.6	59
200	Optimal screening schedules for disease progression with application to diabetic retinopathy. <i>Biostatistics</i> , <b>2018</b> , 19, 1-13	3.7	5
199	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 356-363	14.6	365
198	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , <b>2018</b> , 138, 1599-1601	16.7	16
197	Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>Diabetes Care</i> , <b>2018</b> , 41, 2495-2501	14.6	15
196	Impact of Insulin and Metformin Versus Metformin Alone on $\beta$ Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , <b>2018</b> , 41, 1717-1725	14.6	74
195	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. <i>Diabetes Care</i> , <b>2018</b> , 41, 1696-1706	14.6	89
194	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 777-783	14.6	102
193	Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1507-1516	59.2	73
192	Refining Measurement of Hemoglobin A. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 1433-1435	5.5	1
191	Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 1010-1016	14.6	86
190	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , <b>2017</b> , 48, 1218-1225	6.7	86
189	Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 793-799	14.6	12
188	Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 405-411	14.6	28
187	Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2017;40:777-783. <i>Diabetes Care</i> , <b>2017</b> , 40, e165-e166	14.6	2
186	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 1763-1770	14.6	46
185	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. <i>Hypertension</i> , <b>2017</b> , 70, 907-914	8.5	10

184	The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. <i>Diabetologia</i> , <b>2017</b> , 60, 2084-2091	10.3	45
183	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , <b>2017</b> , 5, e000461	4.5	5
182	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 164-170	14.6	39
181	Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1577-1584	3.2	11
180	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 1969-1977	6.9	69
179	Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 30	8.7	15
178	Fallacies of last observation carried forward analyses. <i>Clinical Trials</i> , <b>2016</b> , 13, 161-8	2.2	117
177	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 323-34	59.2	1956
176	Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. <i>Biostatistics</i> , <b>2016</b> , 17, 178-87	3.7	53
175	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1094	59.2	125
174	Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159958	3.7	12
173	Probabilistic measures of cost-effectiveness. <i>Statistics in Medicine</i> , <b>2016</b> , 35, 3976-86	2.3	0
172	Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5, e002882	6	13
171	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 126-35	16.2	161
170	Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3002-11	11.5	132
169	Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 45-53	27.4	290
168	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimperide in Type 2 Diabetes (CAROLINA). <i>Diabetes and Vascular Disease Research</i> , <b>2015</b> , 12, 164-74	3.3	182
167	Intensive diabetes therapy and ocular surgery in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1722-33	59.2	63



166	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2117-28	59.2	6064
165	The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 108-14	3.2	19
164	Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). <i>Diabetes</i> , <b>2015</b> , 64, 989-98	0.9	32
163	Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. <i>Diabetes</i> , <b>2015</b> , 64, 266-78	0.9	90
162	Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. <i>Diabetes</i> , <b>2015</b> , 64, 631-42	0.9	202
161	Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 118	8.7	35
160	Data sharing is desirable, but benefits should not be exaggerated. <i>BMJ, The</i> , <b>2015</b> , 351, h5508	5.9	1
159	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 232-42	59.2	1739
158	Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes. <i>Clinical Trials</i> , <b>2015</b> , 12, 627-33	2.2	21
157	Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. <i>Diabetes</i> , <b>2014</b> , 63, 1748-62	0.9	159
156	Longitudinal changes in estimated and measured GFR in type 1 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 810-8	12.7	31
155	Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. <i>Diabetes</i> , <b>2014</b> , 63, 739-48	0.9	137
154	Renal outcomes in patients with type 1 diabetes and macroalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 2342-50	12.7	63
153	Intention-to-Treat Analysis <b>2014</b> , 313-322		
152	Applications of the Wei-Lachin multivariate one-sided test for multiple outcomes on possibly different scales. <i>PLoS ONE</i> , <b>2014</b> , 9, e108784	3.7	22
151	Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. <i>Diabetes Care</i> , <b>2014</b> , 37, 39-43	14.6	140
150	Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi-dimensionally censored by therapeutic intervention. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 1288-306	2.3	1
149	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME) <i>Cardiovascular Diabetology</i> , <b>2014</b> , 13, 102	8.7	153

148	Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. <i>Diabetes</i> , <b>2014</b> , 63, 282-90	0.9	138
147	Identifying change points in a covariate effect on time-to-event analysis with reduced isotonic regression. <i>PLoS ONE</i> , <b>2014</b> , 9, e113948	3.7	0
146	Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model. <i>Statistics in Medicine</i> , <b>2013</b> , 32, 220-9	2.3	5
145	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , <b>2013</b> , 10, 289-301	3.3	119
144	Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathy. <i>Ophthalmology</i> , <b>2013</b> , 120, 2580-2586	7.3	8
143	The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2013</b> , 27, 141-9	3.2	41
142	Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata. <i>Statistics in Medicine</i> , <b>2013</b> , 32, 4413-25	2.3	8
141	Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. <i>Diabetes</i> , <b>2013</b> , 62, 3976-86	0.9	162
140	Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. <i>Diabetes</i> , <b>2013</b> , 62, 3561-9	0.9	31
139	Reminiscences of Jerry Cornfield. <i>Clinical Trials</i> , <b>2013</b> , 10, 337-9	2.2	
138	Aortic distensibility in type 1 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 2380-7	14.6	18
137	Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <i>Diabetes Care</i> , <b>2013</b> , 36, 2254-61	14.6	173
136	Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. <i>Diabetes</i> , <b>2013</b> , 62, 3218-23	0.9	30
135	Circulating vitamin D metabolites and subclinical atherosclerosis in type 1 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 2423-9	14.6	27
134	Relation between carotid intima-media thickness and left ventricular mass in type 1 diabetes mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 1534-40	3	5
133	Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort. <i>Journal of Urology</i> , <b>2012</b> , 188, 514-20	2.5	14
132	Circulating vitamin D metabolites and kidney disease in type 1 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 4780-8	5.6	45
131	Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. <i>Diabetes</i> , <b>2012</b> , 61, 2066-73	0.9	216



130	High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27, 1416-23	4.3	33
129	Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. <i>Journal of Urology</i> , <b>2011</b> , 185, 1828-34	2.5	62
128	Effect of rituximab on human in vivo antibody immune responses. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 128, 1295-1302.e5	11.5	76
127	Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2366-76	59.2	390
126	Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. <i>Diabetes</i> , <b>2011</b> , 60, 582-9	0.9	70
125	Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. <i>Atherosclerosis</i> , <b>2011</b> , 214, 462-7	3.1	36
124	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. <i>Pediatric Diabetes</i> , <b>2011</b> , 12, 85-90	3.6	11
123	Power and sample size evaluation for the Cochran-Mantel-Haenszel mean score (Wilcoxon rank sum) test and the Cochran-Armitage test for trend. <i>Statistics in Medicine</i> , <b>2011</b> , 30, 3057-66	2.3	14
122	Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. <i>Circulation</i> , <b>2011</b> , 124, 1737-46	16.7	62
121	Effects of rosiglitazone, glyburide, and metformin on $\beta$ cell function and insulin sensitivity in ADOPT. <i>Diabetes</i> , <b>2011</b> , 60, 1552-60	0.9	164
120	Determining stability of stored samples retrospectively: the validation of glycated albumin. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 286-90	5.5	44
119	Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. <i>Diabetes</i> , <b>2011</b> , 60, 607-13	0.9	101
118	Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. <i>Journal of Immunology</i> , <b>2011</b> , 187, 1998-2005	5.3	51
117	Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. <i>Archives of Internal Medicine</i> , <b>2011</b> , 171, 412-20		238
116	Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 1032-40	6.9	58
115	Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. <i>PLoS ONE</i> , <b>2011</b> , 6, e26471	3.7	33
114	Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i> , <b>2010</b> , 33, 177-83	14.6	34
113	Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. <i>Diabetes Care</i> , <b>2010</b> , 33, 826-32	14.6	114

112	A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. <i>Diabetes</i> , <b>2010</b> , 59, 539-49	0.9	81
111	Point: Intensive glycemic control and mortality in ACCORD--a chance finding?. <i>Diabetes Care</i> , <b>2010</b> , 33, 2719-21	14.6	17
110	Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. <i>Diabetes Care</i> , <b>2010</b> , 33, 1536-43	14.6	207
109	Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 1235-42	6.9	36
108	Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , <b>2010</b> , 33, 1090-6	14.6	259
107	Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 134-42	5.6	138
106	DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. <i>Current Diabetes Reports</i> , <b>2010</b> , 10, 276-82	5.6	89
105	. <i>Wiley Series in Probability and Statistics</i> , <b>2010</b> ,	1.3	27
104	Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. <i>American Journal of Clinical Nutrition</i> , <b>2009</b> , 89, 518-24	7	103
103	Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. <i>Clinical Trials</i> , <b>2009</b> , 6, 565-73	2.2	20
102	Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. <i>Diabetes</i> , <b>2009</b> , 58, 2588-95	0.9	76
101	Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). <i>Circulation</i> , <b>2009</b> , 119, 2886-93	16.7	229
100	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. <i>Pediatric Diabetes</i> , <b>2009</b> , 10, 97-104	3.6	131
99	Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2143-52	59.2	717
98	Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. <i>Diabetes</i> , <b>2008</b> , 57, 995-1001	0.9	340
97	Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i> , <b>2008</b> , 31, 845-51	14.6	431
96	A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. <i>Diabetes Care</i> , <b>2008</b> , 31, 528-33	14.6	88
95	Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. <i>Diabetes Care</i> , <b>2008</b> , 31, 1966-71	14.6	203

94	Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. <i>Diabetes</i> , <b>2008</b> , 57, 218-28	0.9	83
93	Intention-to-Treat Analysis <b>2008</b> , 1		
92	Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. <i>Archives of Internal Medicine</i> , <b>2008</b> , 168, 1867-73		81
91	Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. <i>JAMA Ophthalmology</i> , <b>2008</b> , 126, 1707-15		248
90	National Cooperative Gallstone Study <b>2008</b> , 1		1
89	Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. <i>Statistics in Medicine</i> , <b>2008</b> , 27, 2509-23	2.3	34
88	Type 1 Diabetes TrialNet--an international collaborative clinical trials network. <i>Annals of the New York Academy of Sciences</i> , <b>2008</b> , 1150, 14-24	6.5	81
87	Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study. <i>Hepatology</i> , <b>2007</b> , 3, 209-220	11.2	31
86	A composite design for transition from a preliminary to a full-scale study. <i>Statistics in Medicine</i> , <b>2007</b> , 26, 5014-32	2.3	1
85	Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. <i>Diabetes Care</i> , <b>2007</b> , 30, 2453-7	14.6	394
84	Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. <i>Diabetes</i> , <b>2007</b> , 56, 1153-9	0.9	66
83	The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. <i>Diabetes Care</i> , <b>2007</b> , 30, 2107-12	14.6	57
82	The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. <i>Diabetes</i> , <b>2007</b> , 56, 1913-21	0.9	47
81	The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , <b>2006</b> , 55, 3556-65	0.9	202
80	Effect of weight loss with lifestyle intervention on risk of diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 2102-7	14.6	851
79	Parametric survival models for interval-censored data with time-dependent covariates. <i>Biostatistics</i> , <b>2006</b> , 7, 599-614	3.7	61
78	Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2427-43	59.2	2332
77	Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. <i>Diabetes</i> , <b>2006</b> , 55, 2357-64	0.9	154

76	Operating characteristics of sample size re-estimation with futility stopping based on conditional power. <i>Statistics in Medicine</i> , <b>2006</b> , 25, 3348-65	2.3	10
75	Early Termination of the Diabetes Control and Complications Trial <b>2006</b> , 93-108		
74	A review of methods for futility stopping based on conditional power. <i>Statistics in Medicine</i> , <b>2005</b> , 24, 2747-64	2.3	155
73	Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2643-53	59.2	3690
72	Maximum information designs. <i>Clinical Trials</i> , <b>2005</b> , 2, 453-64	2.2	6
71	Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et al. <i>Diabetes Care</i> , <b>2005</b> , 28, 233; author reply 234-5	14.6	8
70	The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper. <i>Clinical Trials</i> , <b>2004</b> , 1, 417-20	2.2	4
69	The role of measurement reliability in clinical trials. <i>Clinical Trials</i> , <b>2004</b> , 1, 553-66	2.2	171
68	Achieving weight and activity goals among diabetes prevention program lifestyle participants. <i>Obesity</i> , <b>2004</b> , 12, 1426-34		412
67	Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. <i>Statistics in Medicine</i> , <b>2004</b> , 23, 1519-21	2.3	8
66	Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. <i>Diabetes Care</i> , <b>2003</b> , 26, 36-47	14.6	272
65	Over-ruling a group sequential boundary—a stopping rule versus a guideline. <i>Statistics in Medicine</i> , <b>2003</b> , 22, 3347-55	2.3	12
64	Group sequential large sample T2-like chi2 tests for multivariate observations. <i>Statistics in Medicine</i> , <b>2003</b> , 22, 3357-68	2.3	1
63	Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2294-303	59.2	656
62	Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters. <i>Communications in Statistics Part B: Simulation and Computation</i> , <b>2003</b> , 32, 619-639	0.6	1
61	Effects of insulin in relatives of patients with type 1 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1685-91	59.2	655
60	A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 1737-43	14.6	180
59	Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 393-403	59.2	13212

58	Application of robust estimating equations to the analysis of quantitative longitudinal data. <i>Statistics in Medicine</i> , <b>2001</b> , 20, 3411-28	2.3	9
57	Statistical considerations in the intent-to-treat principle. <i>Contemporary Clinical Trials</i> , <b>2000</b> , 21, 167-89		466
56	A flexible stochastic curtailing procedure for the log-rank test. <i>Contemporary Clinical Trials</i> , <b>2000</b> , 21, 428-39		10
55	Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 381-9	59.2	1234
54	Worst-rank score analysis with informatively missing observations in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1999</b> , 20, 408-22		126
53	Link-Based Models for Survival Data with Interval and Continuous Time Censoring. <i>Biometrics</i> , <b>1997</b> , 53, 1199	1.8	27
52	Group sequential monitoring of distribution-free analyses of repeated measures. <i>Statistics in Medicine</i> , <b>1997</b> , 16, 653-68	2.3	13
51	Distribution-Free Marginal Analysis of Repeated Measures. <i>Drug Information Journal</i> , <b>1996</b> , 30, 1017-1028		2
50	Martingales without tears. <i>Lifetime Data Analysis</i> , <b>1995</b> , 1, 361-75	1.3	1
49	Nonparametric test of stochastic ordering for multiple longitudinal measures. <i>Journal of Biopharmaceutical Statistics</i> , <b>1995</b> , 5, 235-43	1.3	2
48	Sequential Monitoring of Survival Data with the Wilcoxon Statistic. <i>Biometrics</i> , <b>1995</b> , 51, 1175	1.8	15
47	Stratified-adjusted versus unstratified assessment of sample size and power for analyses of proportions. <i>Cancer Treatment and Research</i> , <b>1995</b> , 75, 203-23	3.5	4
46	Natural history and course of acquired lactic acidosis in adults. DCA-Lactic Acidosis Study Group. <i>American Journal of Medicine</i> , <b>1994</b> , 97, 47-54	2.4	161
45	Severe hypoglycaemia in Diabetes Control and Complications Trial. <i>Lancet, The</i> , <b>1994</b> , 343, 1097-8	4.0	0
44	Use of spending functions for occasional or continuous monitoring of data in clinical trials. <i>Statistics in Medicine</i> , <b>1993</b> , 12, 2219-31	2.3	22
43	The use of response-adaptive designs in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1993</b> , 14, 471-84		75
42	A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1564-9	59.2	260
41	A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 1373-9	59.2	381

40	Group Sequential Distribution-Free Methods for the Analysis of Multivariate Observations. <i>Biometrics</i> , <b>1992</b> , 48, 1033	1.8	28
39	Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. <i>Statistics in Medicine</i> , <b>1992</b> , 11, 1151-70	2.3	95
38	Power and sample size evaluation for the McNemar test with application to matched case-control studies. <i>Statistics in Medicine</i> , <b>1992</b> , 11, 1239-51	2.3	45
37	Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study. <i>Contemporary Clinical Trials</i> , <b>1992</b> , 13, 62-79		22
36	Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial. <i>Biometrics</i> , <b>1990</b> , 46, 759	1.8	50
35	Permutation tests following restricted randomization procedures. <i>Contemporary Clinical Trials</i> , <b>1990</b> , 11, 150-152		
34	Remembrances of Max Halperin. <i>Statistics in Medicine</i> , <b>1990</b> , 9, 863-70	2.3	1
33	Interim analyses with repeated measurements in a sequential clinical trial. <i>Biometrika</i> , <b>1990</b> , 77, 359-364		40
32	Estimators and Tests in the Analysis of Multiple Nonindependent 2 X 2 Tables with Partially Missing Observations. <i>Biometrics</i> , <b>1988</b> , 44, 513	1.8	16
31	Properties of randomization in clinical trials: Foreword. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 287-288		11
30	Statistical properties of randomization in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 289-311		157
29	Properties of simple randomization in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 312-26		114
28	Properties of permuted-block randomization in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 327-44		198
27	Properties of the urn randomization in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 345-64		237
26	Randomization in clinical trials: conclusions and recommendations. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 365-74		190
25	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. <i>Journal of the American Statistical Association</i> , <b>1988</b> , 83, 339-347	2.8	94
24	External monitoring of a data coordinating center: experience of the National Cooperative Gallstone Study. <i>Contemporary Clinical Trials</i> , <b>1987</b> , 8, 1-11		14
23	Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. <i>Statistics in Medicine</i> , <b>1986</b> , 5, 73-83	2.3	32



22	Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification. <i>Biometrics</i> , <b>1986</b> , 42, 507	1.8	264
21	Major issues in the organization and implementation of the National Cooperative Gallstone Study (NCGS). <i>Contemporary Clinical Trials</i> , <b>1984</b> , 5, 1-12		3
20	Effects of dose relative to body weight in the National Cooperative Gallstone Study: a fixed-dose trial. <i>Contemporary Clinical Trials</i> , <b>1983</b> , 4, 125-31		2
19	Central laboratory quality control in the National Cooperative Gallstone Study. <i>Contemporary Clinical Trials</i> , <b>1983</b> , 4, 101-23		11
18	The National Cooperative Gallstone Study and current management of cholesterol cholelithiasis—two views. <i>Gastroenterology</i> , <b>1983</b> , 84, 644-648	13.3	8
17	A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: the National Cooperative Gallstone Study. <i>Hepatology</i> , <b>1982</b> , 2, 187-201	11.2	42
16	National Cooperative Gallstone Study. <i>Gastroenterology</i> , <b>1982</b> , 82, 638-646	13.3	79
15	Pretreatment Biliary Lipid Composition in White Patients with Radiolucent Gallstones in the National Cooperative Gallstone Study. <i>Gastroenterology</i> , <b>1982</b> , 83, 738-752	13.3	97
14	Sequential Clinical Trials for Normal Variates Using Interval Composite Hypotheses. <i>Biometrics</i> , <b>1981</b> , 37, 87	1.8	8
13	Introduction to sample size determination and power analysis for clinical trials. <i>Contemporary Clinical Trials</i> , <b>1981</b> , 2, 93-113		737
12	Sample Size Determinations for $r \times c$ Comparative Trials. <i>Biometrics</i> , <b>1977</b> , 33, 315	1.8	46
11	Phasic heart rate responses: different patterns in black and in white newborns. <i>Psychosomatic Medicine</i> , <b>1975</b> , 37, 326-32	3.7	2
10	On stepwise discriminant analyses applied to physiologic data. <i>Psychophysiology</i> , <b>1974</b> , 11, 703-9	4.1	28
9	On a Stepwise Procedure for Two Population Bayes Decision Rules Using Discrete Variables. <i>Biometrics</i> , <b>1973</b> , 29, 551	1.8	9
8	Depression as a symptom of alcoholism: search for a phenomenon. <i>Journal of Abnormal Psychology</i> , <b>1968</b> , 73, 195-7	7	43
7	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data		26
6	Randomization as a Basis for Inference. <i>Wiley Series in Probability and Statistics</i> , 97-132	1.3	
5	Stratification. <i>Wiley Series in Probability and Statistics</i> , 133-146	1.3	

- 4 Issues in the Design of Clinical Trials. *Wiley Series in Probability and Statistics*,15-36 1.3
- 3 Response-Adaptive Randomization in Practice. *Wiley Series in Probability and Statistics*,231-242 1.3
- 2 Randomization for Balancing Treatment Assignments. *Wiley Series in Probability and Statistics*,37-66 1.3
- 1 Restricted Randomization in Practice. *Wiley Series in Probability and Statistics*,147-168 1.3